Abstract: The present invention provides a method for preventing endotoxin-associated shock in a subject which comprises administering to the subject an amount of a BPI protein effective to bind to endotoxin so as to prevent endotoxin associated shock in the subject. This invention further provides a method for treating a subject suffering from endotoxin-associated shock which comprises administering to the subject an amount of a BPI protein effective to bind endotoxin so as to treat the subject suffering from endotoxin-associated shock.

Abstract: A family of compounds effective in inhibiting interleukin-1 (IL-1) production, interleukin-6 (IL-6), tumor necrosis factor (TNF) production, and the production of other leukocyte derived cytokines is comprised of oligomers and polymers of .alpha.1-4 linked L-guluronic acid residues which may be administered to a human or mammal in an amount sufficient to inhibit the production effect of leukocyte-derived cytokines. The inhibition of IL-1, IL-6 and TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

Abstract: The present invention relates to a method of treating diseases associated with elevated levels of interleukin 1 (IL-1) including inflammatory diseases such as arthritis, skin hypersensitivity and endotoxemia. More specifically, the invention relates to a method for the treatment of such diseases in warm-blooded animals, such as humans, which comprises the administration of a therapeutically effective amount of an aromatic diamidine, sufficient to inhibit IL-1 release from IL-1 producing cells. The aromatic diamidine can also be used to block interleukin 6 (IL-6) and tumor necrosis factor from cells producing these cytokines.

Abstract: A method for the treatment of patients with acute cardiovascular compromise by administering a therapeutically effective amount of thyroid hormones. Methods of administration are included.

Abstract: In one variant, the invention provides a method of enhancing the activity of phagocytes including macrophages, and in a further variant, a method of modulating the cellular or humoral immune response to warm blooded animals. The invention also provides a method of reducing the adverse effects of stress in warm blooded animals. This is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M.sub.1 --O--Y, an ethereal monosubstitution of monosaccharide derivatives having the general formula M.sub.2 --O--Y, or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In the first variant, the above substances are administered in an amount effective to enhance the microbicidal activity of phagocytes, including macrophages in a normal to depressed state of activation or macrophages already activated in response to infection.

Abstract: The invention provides an orally administered pharmaceutical composition for use in gastrointestinal washes, particularly for diagnostic use, or as a cathartic laxative, of the type containing polyethyleneglycol, anhydrous sodium sulphate, sodium bicarbonate, sodium chloride and potassium chloride, characterized by also containing the following components: saccharin, acesulfame-K and a flavoring chosen from the following: mandarin, fresh fruit flavoring.

Abstract: Cyclic pentapeptides of the formula:cyclo (-X.sup.1 -X.sup.2 -X.sup.3 -X.sup.4 -X.sup.5 -) (I)wherein X.sup.n (n=1-5) represents amino acid residues. These compounds are useful as hypotensive drugs.

Abstract: Shipping fever, and other stress-related diseases in livestock, are treated by administration of a microencapsulated composition comprising IL-2 conjugated with a polyoxyethylene polymer, and mixed with a release-modulating amount of humen serum albumin. The microcapsules are administered parenterally, and release an effective amount of conjugated IL-2 continuously over a period of 14-30 days. These microcapsules are also effective in the treatment of cancer in mammals.

Abstract: Pharmaceutical compositions useful for the treatment or prophylaxis of Gram-negative bacteremia or septic shock contain a bactericidal effective amount of polyclonal immunoglobulins against Gram-negative bacteria and a blood clot-dissolving effective amount of protein C. The compositions may further contain one or more protein C cofactors and monoclonal antibodies against Gram-negative bacterial endotoxins.A method for the treatment or prophylaxis of Gram-negative bacteremia or septic shock comprises administering, either together or separately, a bactericidal effective amount of polyclonal immunoglobulins against Gram-negative bacteria and a blood clot-dissolving effective amount of protein C. The method may optionally include administering one or more protein C cofactors and monoclonal antibodies against Gram-negative bacterial endotoxins.

Abstract: The invention relates to a therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein, an effective amount either, of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.4 stant for H or CH.sub.3 or C.sub.2 H.sub.5,R.sub.2 stands for H or NO.sub.2 andR.sub.3 stands for NHR.sub.4 or CH.sub.3 or C.sub.2 H.sub.5alone or of a mixture of said compound with a cyclooxygenase blocker.

Abstract: A glycerin derivative having the following formula (I) or (I') and a pharmacologically acceptable salt thereof are useful to treat diseases caused by the platelet activating factor.

Abstract: Bacterial endotoxins are inhibited by a non-toxic, water-soluble, pharmaceutically acceptable peroxydiphosphate compound in contact with bacterial endotoxin.

Abstract: An opiate antagonist or a pharmaceutically acceptable salt thereof is used to treat emotional numbness associated with Post Traumatic Stress Disorder and other psychopathologic conditions.

Abstract: An opiate antagonist or a pharmaceutically acceptable salt thereof is used to treat emotional numbness associated with Post Traumatic Stress Disorder and other psychopathologic conditions. Opiate antagonist or a pharmaceutically acceptable salt thereof is also used to treat coma.

Abstract: The use of a compound of formula (I) or a physiologically acceptable salt or hydrate thereof in the treatment, relief or prevention of the effects of cerebral ischaemia ##STR1## Compounds of formula (I) are described in UK Published Patent Application No. 2157691A.The compounds of formula (I) have been found to protect mammals, including man, against neuronal damage resulting from cerebral ischaemia.The preferred compound for use in this indication is (.+-.)-trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]-benzodioxino[2,3-c]- pyrrole (formula (I), R=H, R.sup.1 =F, R.sup.2 =H), especially in the form of its hydrochloride salt.

Abstract: A method for treating shock in a patient, which comprises administering to the patient a therapeutically effective amount of a diazepinone of the general formula: ##STR1## wherein A represents a 5,11-dihydro-6H-pyrido[2,3-b] [1,4] benzodiazepin-6-one group bound in the 11-position; a 5,10-dihydro-11H-dibenzo [b,e] [1,4] diazepin-11-one group bound in the 5-position; a 5,11-dihydro-10H-pyrido [3-2b] [1-4] benzodiazepin-10-one group bound in the 5-position; a 4,9-dihydro-10H-thieno [3,4-b] [1,5] benzodiazpin-10-one group bound in the 4-position, unsubstituted or substituted at the 1- or 3-position or both in the 1- and 3-position by an alkyl group having from 1 to 4 carbon atoms, or in the 3-positionby chlorine, fluorine or bromine; a 6-11-dihydro-5H-pyrido [2,3-b] [1,5] benzodiazepin-5-one group bound in the 11-position; or a 1-methyl-1,4,9,10-tetrahydropyrrolo-[3,2-b] [1,5] benzodiazepin-10-one group bound in the 4-position, unsubstituted or substituted at the 3-position by methyl or methyl or chlorine;R.sub.

Abstract: The present invention provides compositions of matter and methods for treating a human subject to prevent leakage of serum albumin from capillary endothelial junctions during a period of increased capillary permeability. The method comprises administering to the human subject an effective capillary pore sealing amount of a macromolecule which is biodegradable, non-toxic, globular in shape, with a molecular weight range from about 100,000 daltons to about 1,000,000 daltons and a pharmaceutically acceptable carrier. The composition of matter comprises a fraction derived from hydroxyethyl starch.

Abstract: A polypeptide transforming growth factor found in porcine platelets, having activity in the TGF-.beta. assay and a molecular weight of about 25 kDa. The factor is a heterodimer, one chain of which has an N-terminal sequence very different from human platelet TGF-.beta., and the other chain of which has an N-terminal sequence identical to that of human platelet TGF-.beta.. The factor is purified using gel filtration and reverse phase HPLC.

Abstract: A highly concentrated solution is provided which is both hyperosmotic and hyperoncotic with respect to blood plasma and has utility in treating patients experiencing or threatening to experience hypodynamic shock. The physiologically acceptable solution comprises a crystalloid to provide a osmolarity in excess of 5000 mOsms and a colloid to provide an oncocity in excess of 200 mm Hg. The solution is easily transported and administered by a single, rapid infusion of about less than about 1 ml/kg of body weight and results in a rapid and sustained normalization of circulatory function.

Abstract: A physiologically acceptable solution which is both hyperosmotic and hyperoncotic with respect to blood plasma and has utility in treating patients experiencing or threatening to experience hypodynamic shock. The physiologically acceptable solution comprises a hyperosmotic concentration of a crystalloid (in excess of about 1800 mOsms) and hyperoncotic concentration of a colloid (in excess of about 30 mm Hg). The physiologically acceptable solution is easily administered by single, rapid infusion of approximately 4 to 5 ml/kg of body weight and results in a rapid and sustained normalization of circulatory function.

Abstract: The invention relates to an improved cardioplegic solution for reducing ischemic damage to the heart during operations and/or transplantation. The invented solution contains adenosine, hypoxanthine and ribose in addition to the electrolytes contained in standard cardioplegic solutions.

Abstract: An electronic unit for the treatment of venomous snakes, insects, spiders, and allergic reaction associated with plants. The electronic treatment is used also for the pain associated with arthritis, gout, headaches, and nerve pain. The unit consists of electric DC current powered by a 9 volt battery. This unit will provide DC current between 18 and 25 kv. A pulsating current with low amperage. The battery is one 9 volt battery rechargeable preferred or the Energizer battery (not included). To install battery open the base of the unit, install battery and replace the cover. To test push switch and you will hear and see an electrical discharge between the two inside electrodes. The suggested use for treatment of snake bites, place 1 electrode on skin as close to the bite as possible. The other electrode on the skin to use as a ground. Both electrodes touching the skin. Push the spring loaded trigger ON to release the current. Hold in contact with skin for 2 seconds, release 10 seconds.

Abstract: Disclosed are pharmaceutical compositions containing certain heterocylcic sulphonamido azo compounds for enhancing oxygen availability to mammalian tissue.

Abstract: The present invention is directed to a method of inhibiting to onset of septicemia and endotoxemia. The methods comprise administering to a warm-blooded animal an effective amount of a pharmaceutical composition comprising Monophosphoryl lipid A in combination with a pharmaceutically acceptable carrier.

Abstract: There is disclosed a process for treating gram negative septicemia/endotoxemia to decrease lung damage in a host by parenterally administering a therapeutically effective amount of antithrombin III and alpha-1-proteinase inhibitor.

Abstract: A method of prophylactics with respect to detoxification of Staphylococcus aureus and other toxins by ascorbic acid, salts and esters, topically applied by means of carriers which are otherwise regularly employed in the area where Staphylococcus aureus or other bacteria colonize, such as a pharmacological appliance including gauze pads, an absorbant mass or pad associated with menses, douches, and contraceptive compositions.

Abstract: A method of prophylactics with respect to deodorization by ascorbic acid, salts and esters, topically applied by means of carriers which are otherwise regularly employed in the vaginal area, such as a pharmacological appliance including gauze pads, an absorbant mass or pad associated with menses, douches, and contraceptive compositions.

Abstract: A method for treating adult respiratory distress syndrome (ARDS) and sepsis in a patient in need thereof which comprises administering to said patient an antibody to complement component C5a or the des Arg derivative thereof in an amount effective to treat ARDS and sepsis.

Abstract: A process for the total or partial elimination of aspartic acid and glutamic acid from a protein hydrolyzate or a mixture of aminoacids is described, which consists of passing the hydrolyzate or mixture of aminoacids in solution on an anion exchange resin and then washing with water or eluting the aminoacids from the resin. Aspartic acid and glutamic acid are at least partially separated from the other aminoacids because of their affinity for the resin which is greater than the affinity of the other aminoacids. The resulting mixtures of aminoacids may be used as such or may be further adjusted by addition of valine, leucine, isoleucine, and arginine to give products valuable in clinical nutrition.

Abstract: The present invention is directed to a method of inhibiting the onset of acute radiation syndrome caused by the exposure of warm-blooded animals to a whole body dose of at least about 100 rads of x-radiation. The invention is also directed to a method of inhibiting the onset of septicemia. The methods comprise administering to a warm-blooded animal an effective amount of a pharmaceutical composition comprising refined detoxified endotoxin in combination with a pharmaceutically acceptable carrier.

Abstract: This invention relates to a method of prophylaxis with respect to Toxic Shock Syndrome in warm blooded animals, comprising the placing of a propylactically effective dosage of ascorbic acid in the vagina or in the area of the vagina.

Abstract: There is disclosed a polyprenylcarboxylic acid amide of the formula: ##STR1## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group, R.sup.2 represents a hydrogen atom or a group of the formula: --COOR.sup.4 in which R.sup.4 represents a lower alkyl group, R.sup.3 represents a hydrogen atom or an OH group and n represents an integer of 1 to 6.